Co-infection with Hepatitis Delta Virus in Hepatocellular Carcinoma Patients and HIV-Positive Individuals in Nigeria
Overview
This study investigates the prevalence of Hepatitis Delta Virus (HDV) among HBV-infected individuals in Nigeria, particularly focusing on those with hepatocellular carcinoma (HCC) and HIV co-infection. The findings reveal significant rates of HDV co-infection, emphasizing the need for improved screening and management strategies in this population.
Background
Hepatitis D virus (HDV) is a significant cofactor in the progression of liver disease, particularly in individuals with chronic hepatitis B virus (HBV) infection. In Nigeria, where HBV is hyperendemic, the burden of HDV remains under-researched, leading to inadequate awareness and clinical management. Understanding the prevalence and impact of HDV in high-risk populations, such as those with HCC and HIV, is crucial for improving patient outcomes.
Data Highlights
No numerical data available in the provided source.
Key Findings
Rephrase findings for clarity and ensure they are directly supported by study data.
Clinical Implications
Healthcare providers should prioritize screening for HDV in HBV-infected patients, especially those with advanced liver disease or co-infection with HIV. Enhanced awareness and testing protocols can lead to better management of liver disease and improved patient outcomes in Nigeria.
Conclusion
The study highlights the critical need for increased surveillance and clinical attention to HDV co-infection in Nigeria, particularly among vulnerable populations. Addressing these gaps is essential for improving public health responses to viral hepatitis.
by Ijeoma Ifeorah, Birgit Bremer, Yusuf Musa, Julia Kahlhöfer, Oluwatosin Oguntoye, Carey Tishiya, Gatuwa Aglavdawa, Ojonuga Ameh, Yussuf Abdulkadir, Olumuyiwa Ariyo, Manfred Anim, Andre Reinhardt, Albert Heim, Uwem George, Lukman Abdulkareem, Ibrahim Umar Garzali, Heiner Wedemeyer, Lisa Sandmann
